1. Pink Sheet

Government Pharma Investigations Target Pricing, Opioids, Trade Practices

 
• By Brenda Sandburg

While DOJ probes have declined in last few years, 13 of top 25 pharma companies are dealing with ongoing inquiries of marketing and pricing practices.

Business, Technology, Internet and network concept. Businessman working on the tablet of the future, select on the virtual display: Investigation

Once the fodder for billion dollar settlements, government investigations of the pharmaceutical industry have fallen off in the last few years. But behind the scenes the Department of Justice continues to probe several practices, including pricing, opioid marketing, and relationships with charities and pharmacy benefit managers (PBMs).

A look at recent Securities and Exchange Commission filings and financial statements of more than 20 of the top revenue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 
• By Bridget Silverman

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.